Eli Lilly and Company (NYSE:LLY) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 30, the company announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study,

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback is a buy-the-dip opportunity.

Eli Lilly launches Mounjaro KwikPen in India, offering adults with type 2 diabetes and obesity a once-weekly, prescription-only treatment.

Texas Attorney General Ken Paxton alleges that Eli Lilly bribed Texas medical providers to provide the company's drugs. Eli Lilly denies the claims.

Texas Attorney General Ken Paxton filed a lawsuit against Eli Lilly, accusing the drug maker of bribing doctors to prescribe their medications. Paxton said the quid pro quo arrangements tainted millions of dollars of claims to Texas Medicaid.

Eli Lilly and Company (NYSE:LLY) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Eli Lilly and Company (NYSE:LLY) revealed the topline results of the SURPASS-CVOT Phase 3 trial, which showed that Mounjaro (tirzepatide) was non-inferior to Trulicity (dulaglutide) in reducing significant cardiovascular events (MACE-3) among more than 13,